Skip to content

Clinical study on reducing the incidence of hiccups of Remimazolam

Clinical study on reducing the incidence of hiccups of Remimazolam

Status
Active, not recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093918
Enrollment
Unknown
Registered
2024-12-13
Start date
2024-12-15
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Remimazolam Hiccups

Interventions

Group R20:Remimazolam 0.2mg/kg was given intravenously at a rate of 20s. BIS was used to observe the sedative effect. The primary outcome measure was the incidence of hiccups within 4 minutes.
Group R40:Remimazolam 0.2mg/kg was given intravenously at a rate of 40s. BIS was used to observe the sedative effect. The primary outcome measure was the incidence of hiccups within 4 minutes.
Group R60:Remimazolam 0.2mg/kg was given intravenously at a rate of 60s. BIS was used to observe the sedative effect. The primary outcome measure was the incidence of hiccups within 4 minutes.

Sponsors

Guangzhou Women and Children's Medical Center, Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Study population: Adult patients with ASA scores I-II who require general anesthesia in our hospital Inclusion criteria: 1. General anesthesia 2. ASA rating levels I-II 3. Age range: 18-60 years old

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Severe cardiopulmonary dysfunction and systemic diseases 2. History of phrenic nerve injury or surgery 3. Full stomach

Design outcomes

Primary

MeasureTime frame
incidence of hiccups ;

Countries

China

Contacts

Public ContactQianqi Qiu

Guangzhou Women and Children's Medical Center, Guangzhou Medical University

qiuqianqi1216@sina.com+86 136 3239 1377

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026